# Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide

> **NCT01043146** · PHASE1 · COMPLETED · sponsor: **Corimmun GmbH** · enrollment: 50 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** COR-1
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01043146
- **Lead sponsor:** Corimmun GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01043146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01043146, "Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01043146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*